Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.39 |
| ▸ | ACACA | Q13085 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 5/20 | 0.32 |
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351936 | 0.90 | ACACB (0.49) | ACACBACACATHRBLMNAEDNRA | |
| SCHEMBL2353778 | 0.89 | ACACB (0.44) | ACACBACACACNR1CNR2EDNRA | |
| SCHEMBL13548092 | 0.86 | ACACB (0.44) | ACACBACACAEDNRA | |
| SCHEMBL2355518 | 0.86 | ACACB (0.35) | ACACBACACATHRBLMNAEDNRA | |
| SCHEMBL2350180 | 0.85 | ACACB (0.41) | ACACBACACACNR1CNR2EDNRA | |
| SCHEMBL2353015 | 0.85 | THRB (0.41) | ACACBACACACNR1CNR2THRB | |
| SCHEMBL13963619 | 0.84 | ACACB (0.34) | ACACBACACACNR1CNR2THRB | |
| SCHEMBL13963622 | 0.83 | ACACB (0.33) | ACACBACACACNR1CNR2 | |
| SCHEMBL13548102 | 0.83 | ACACB (0.36) | ACACBACACACNR1CNR2THRB | |
| SCHEMBL13548038 | 0.81 | THRB (0.42) | ACACBACACACNR1CNR2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | claimed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | ACACB 310/4885ACACA 541/4885CNR1 783/4885 |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | CYP46A1, LIPC, CYP27A1 | ACACB 85/4885ACACA 90/4885CNR1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.